CG Oncology

enGene

This clinical-stage biotechnology company develops non-viral gene therapies for patients with high-risk, non-muscle invasive bladder cancer and other mucosal tissue diseases.

Aura Biosciences

This biotechnology company develops virus-like drug conjugates to treat patients with solid tumours, specifically targeting ocular and bladder cancers.

ArTara Therapeutics

This clinical-stage biopharmaceutical company develops cell therapies and replacement treatments for patients with non-muscle invasive bladder cancer and rare metabolic diseases.

UroGen Pharma

This company develops and commercialises hydrogel-based medicines for patients with urological and specialty cancers, including treatments for low-grade upper tract urothelial carcinoma and bladder cancer.

Rainier Therapeutics

The company develops targeted antibody therapies for patients with early-stage and metastatic bladder cancer.

Emergence

This biopharmaceutical company develops antibody drug conjugates to treat high-need cancers including bladder and triple-negative breast cancer.

Replimune Group

The company develops oncolytic immunotherapies for cancer patients, including its first commercial treatment for adults with advanced melanoma.

TORL BioTherapeutics

This biopharmaceutical company develops antibody-drug conjugates and monoclonal antibodies to treat various cancers for patients with unmet medical needs.